Valeant Names Three New Directors to BoardBy
Valeant Pharmaceuticals International, Inc. reports that Dr. Fred Eshelman, Mr. Stephen Fraidin and Mr. Thomas W. Ross, Sr. have joined its Board of Directors as independent directors, effective March 8, 2016. Valeant also announced that Dr. Anders Lonner has stepped down as a director due to other priorities and personal commitments, effective March 8, 2016. With these changes, Valeant has increased the size of its board to 14 members, 12 of whom are independent.
Fred Eshelman is a 35-year veteran of the pharmaceutical industry and is the founder and former chief executive officer and executive chairman of Pharmaceutical Product Development, Inc. Dr. Eshelman was also the founding chairman of Furiex Pharmaceuticals, Inc., a drug development company.
Stephen Fraidin is a mergers and acquisition lawyer, having worked in the industry for more than 40 years. He is currently vice chairman at Pershing Square Capital Management L.P. Thomas W. Ross served as president of the University of North Carolina from 2011 to 2016. Before that, he served as a North Carolina Superior Court judge for 17 years.
Source: Valeant Pharmaceuticals